BRCA1 and prostate carcinoma: Furthermore, cancers with PALB2 (p.M723X) and BRCA1 (p.Q262H) mutations can also benefit from PARP inhibitors, which are recommended in professional guidelines for treating breast, ovarian, and prostate cancer [47,48,49,50,51,52].